FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Per Omvik

Research Profile

Disorders

Chemicals & Drugs

Physiology

Hemodynamics

Procedures

Co-author Network

Publications

TOP 3
Anders M Greve; Mai T Lønnebakken; Markku S Nieminen; Peter M Okin; Michael H Olsen; Per Omvik; Vittorio Palmieri; Jonathan Bella; Kurt Boman; Björn Dahlöf; Richard B Devereux; Eva Gerdts; Kristian Wachtell
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
Michael H Olsen; Kristian Wachtell; Hans Ibsen; Lars Lindholm; Sverre E Kjeldsen; Per Omvik; Markku S Nieminen; Björn Dahlöf; Peter M Okin; Richard B Devereux
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy.
Michael H Olsen; Kristian Wachtell; Gareth Beevers; Björn Dahlöf; Giovanni de Simone; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Paulette A Lyle; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Per Omvik (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Anders M Greve; Mai T Lønnebakken; Markku S Nieminen; Peter M Okin; Michael H Olsen; Per Omvik; Vittorio Palmieri; Jonathan Bella; Kurt Boman; Björn Dahlöf; Richard B Devereux; Eva Gerdts; Kristian Wachtell
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
American journal of hypertension 2012;25(9):1017-23.
2011: Michael H Olsen; Kristian Wachtell; Hans Ibsen; Lars Lindholm; Sverre E Kjeldsen; Per Omvik; Markku S Nieminen; Björn Dahlöf; Peter M Okin; Richard B Devereux
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy.
Journal of hypertension 2011;29(5):997-1004.
2009: Michael H Olsen; Kristian Wachtell; Gareth Beevers; Björn Dahlöf; Giovanni de Simone; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Paulette A Lyle; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2009;27(3):567-74.
2009: Einar Skulstad Davidsen; Tor Hervig; Per Omvik; Eva Gerdts
Left ventricular long-axis function in treated haemochromatosis.
The international journal of cardiovascular imaging 2009;25(3):237-47.
2009: Einar Skulstad Davidsen; Per Omvik; Tor Hervig; Eva Gerdts
Left ventricular diastolic function in patients with treated haemochromatosis.
Scandinavian cardiovascular journal : SCJ 2009;43(1):32-8.
2009: Sverre E Kjeldsen; Richard B Devereux; Darcy A Hille; Paulette A Lyle; Björn Dahlöf; Stevo Julius; Jonathan M Edelman; Steven M Snapinn; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Blood pressure 2009;18(6):348-61.
2007: Tonje Amb Aksnes; Sverre E Kjeldsen; Morten Rostrup; Per Omvik; Tsushung Hua; Stevo Julius
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Hypertension 2007;50(3):467-73.
2007: Einar Skulstad Davidsen; Knut Liseth; Per Omvik; Tor Hervig; Eva Gerdts
Reduced exercise capacity in genetic haemochromatosis.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2007;14(3):470-5.
2007: Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Katherine E Harris; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Darcy A Hille; Björn Dahlöf
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Current medical research and opinion 2007;23(2):259-70.
2007: Eva Gerdts; Kristian Wachtell; Per Omvik; Jan Erik Otterstad; Lasse Oikarinen; Kurt Boman; Björn Dahlöf; Richard B Devereux
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Hypertension 2007;49(2):311-6.
2006: Eva Gerdts; Hans Björnstad; Richard B Devereux; Per Lund-Jhansen; Einar S Davidsen; Per Omvik
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
Blood pressure 2006;15(4):220-6.
2005: Sverre E Kjeldsen; Paulette A Lyle; Andrew M Tershakovec; Richard B Devereux; Suzanne Oparil; Björn Dahlöf; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Hans Wedel
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Expert opinion on emerging drugs 2005;10(4):729-45.
2005: Eigil Fossum; andreas moan; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; Steven M Snapinn; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Björn Dahlöf
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;46(5):770-5.
2005: Giovanni de Simone; Kristian Wachtell; Vittorio Palmieri; Darcy A Hille; Gareth Beevers; Björn Dahlöf; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Richard B Devereux
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Circulation 2005;111(15):1924-31.
2005: Frej Fyhrquist; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Darcy A Hille; Paulette A Lyle; Jonathan Edelman; Steven M Snapinn; Hans Wedel
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Hypertension 2005;45(4):580-5.
2005: Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Katherine E Harris; Hans Wedel
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(3):152-8.
2005: Hans Ibsen; Michael H Olsen; Kristian Wachtell; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Hypertension 2005;45(2):198-202.
2005: Jorge R Kizer; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Kristian Wachtell; Jonathan Edelman; Steven M Snapinn; Katherine E Harris; Richard B Devereux
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Hypertension 2005;45(1):46-52.
2004: Hans Ibsen; Kristian Wachtell; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Journal of hypertension 2004;22(9):1805-11.
2004: Eva M Staal; Ottar Nygård; Per Omvik; Eva Gerdts
Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians.
Blood pressure monitoring 2004;9(3):167-72.
2004: Henrik M Reims; Sverre E Kjeldsen; W E Brady; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):381-9.
2004: Per Omvik; Per Lund-Johansen
[Why not always diuretics?].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2004;124(10):1419-20.
2004: Eva Gerdts; Per Omvik; Rune Mo; Sverre E Kjeldsen
[Hypertension and heart disease].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2004;124(6):802-5.
2004: Per Omvik; Bjørn Bratland; Gerhard Gerhardsen; Kjell Gisholt; Terje Risanger; Tore Smedsrud; Sverre E Kjeldsen
[Treatment of hypertension in patients with left ventricular hypertrophy].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2004;124(6):788-91.
2004: Aud Høieggen; Michael H Alderman; Sverre E Kjeldsen; Stevo Julius; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Cong Chen; Björn Dahlöf
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Kidney international 2004;65(3):1041-9.
2004: Henrik M Reims; Suzanne Oparil; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; William E Brady; Frej Fyhrquist; Hans Ibsen; Lars H Lindholm; Per Omvik; Hans Wedel; Gareth Beevers; Ulf de Faire; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Björn Dahlöf
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Blood pressure 2004;13(6):376-84.
2003: Kristian Wachtell; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Peter M Okin; Per Omvik; Suzanne Oparil; Hans Wedel; Steven M Snapinn; Peter Aurup
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Annals of internal medicine 2003;139(11):901-6.
2003: Richard B Devereux; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Peter Aurup; Gareth Beevers; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Sigrid Helle Berg; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Annals of internal medicine 2003;139(3):169-77.
2003: Per Omvik; Gerhard Gerhardsen
The Norwegian office-, home-, and ambulatory blood pressure study (NOHA).
Blood pressure 2003;12(4):211-9.
2002: Sverre E Kjeldsen; Björn Dahlöf; Richard B Devereux; Stevo Julius; Peter Aurup; Jonathan Edelman; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
JAMA : the journal of the American Medical Association 2002;288(12):1491-8.
2002: Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael H Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2002;20(9):1879-86.
2002: Roy Olsen; Aina Amlie; Per Omvik
Twenty-four-hour ambulatory blood pressure monitoring in atrial fibrillation.
Blood pressure monitoring 2002;7(3):149-56.
2002: Eva Gerdts; Hans Bjornstad; Sigurd Toft; Richard B Devereux; Per Omvik
Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
Journal of hypertension 2002;20(6):1223-9.
2002: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):1004-10.
2002: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):995-1003.
2001: J Doyle; Per Omvik; Steve Arikian; Julian Casciano; Roman Casciano; M A Gonzalez; Raul Arocho
A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
Managed care interface 2001;14(3):82-7.
2001: Einar Svarstad; Eva Gerdts; Per Omvik; Jarle Ofstad; Bjarne M Iversen
Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus.
Kidney & blood pressure research 2001;24(1):64-70.
2000: Kjell Vikenes; Per Omvik; Marit Farstad; Jan Erik Nordrehaug
Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter.
American heart journal 2000;140(4):690-6.
2000: Per Omvik; Eva Gerdts; Ole L Myking; Per Lund-Johansen
Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension.
American heart journal 2000;140(4):624-30.
2000: Sverre E Kjeldsen; Björn Dahlöf; R B Devereux; Stevo Julius; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
American journal of hypertension 2000;13(8):899-906.
1999: Eva Gerdts; Per Lund-Johansen; Per Omvik
Reproducibility of salt sensitivity testing using a dietary approach in essential hypertension.
Journal of human hypertension 1999;13(6):375-84.
1999: Per Omvik; Eva Gerdts; Ole L Myking; Per Lund-Johansen
Similar central hemodynamics in salt-sensitive and salt-resistant hypertensive patients.
Blood pressure 1999;8(4):233-41.
1998: Björn Dahlöf; Richard B Devereux; Stevo Julius; Sverre E Kjeldsen; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Thomas Hedner; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Hypertension 1998;32(6):989-97.
1998: Eva Gerdts; Einar Svarstad; S Aanderud; Ole L Myking; Per Lund-Johansen; Per Omvik
Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months.
American journal of hypertension 1998;11(10):1178-87.
1998: Eva Gerdts; Per Lund-Johansen; Per Omvik
Factors influencing left ventricular mass in salt sensitive and salt resistant essential hypertensive patients.
Blood pressure 1998;7(4):223-30.
1998: Bernd Timmermann; R Mo; Friedrich C Luft; Eva Gerdts; Andreas Busjahn; Per Omvik; G H Li; Herbert Schuster; T F Wienker; Margret R Hoehe; Per Lund-Johansen
Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study.
Kidney international 1998;53(6):1455-60.
1997: Eva Gerdts; Ole L Myking; Per Lund-Johansen; Per Omvik
Factors influencing LVM in hypertensive type-1 diabetic patients.
Blood pressure 1997;6(4):197-202.
1997: Björn Dahlöf; R Devereux; Ulf de Faire; Frej Fyhrquist; Thomas Hedner; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
American journal of hypertension 1997;10(7 Pt 1):705-13.
1996: Eva Gerdts; E Svarstad; Ole L Myking; Per Lund-Johansen; Per Omvik
Salt sensitivity in hypertensive type-1 diabetes mellitus.
Blood pressure 1996;5(2):78-85.
1996: Per Omvik
How smoking affects blood pressure.
Blood pressure 1996;5(2):71-7.
1995: R Mo; Per Omvik; Per Lund-Johansen
The Bergen blood pressure study: offspring of two hypertensive parents have significantly higher blood pressures than offspring of one hypertensive and one normotensive parent.
Journal of hypertension 1995;13(12 Pt 2):1614-7.
1995: Per Omvik; O B Herland; E Thaulow; I Eide; R Midha; R R Turner
Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension.
Journal of human hypertension 1995;9 Suppl 1():S17-24.
1995: Per Omvik; Ole L Myking
Unchanged central hemodynamics after six months of moderate sodium restriction with or without potassium supplement in essential hypertension.
Blood pressure 1995;4(1):32-41.
1995: R Mo; J E Nordrehaug; Per Omvik; Per Lund-Johansen
The Bergen Blood Pressure Study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families.
Blood pressure 1995;4(1):16-22.
1994: Eva Gerdts; Ole L Myking; Per Omvik
Salt sensitive essential hypertension evaluated by 24 hour ambulatory blood pressure.
Blood pressure 1994;3(6):375-80.
1994: R Mo; O L Myking; Per Lund-Johansen; Per Omvik
The Bergen Blood Pressure Study: inappropriately low levels of circulating atrial natriuretic peptide in offspring of hypertensive families.
Blood pressure 1994;3(4):223-30.
1994: Per Omvik; E Thaulow; O B Herland; I Eide; R Midha; R R Turner
A long-term, double-blind, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study.
British journal of clinical practice. Supplement 1994;73():23-30.
1994: R Mo; Per Omvik; Per Lund-Johansen
The Bergen Blood Pressure Study. Estimated prevalence of postural hypotension is influenced by the alerting reaction to blood pressure measurement.
Journal of human hypertension 1994;8(3):171-6.
1994: Per Lund-Johansen; Per Omvik; W White
Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment.
The American journal of cardiology 1994;73(3):44A-49A.
1993: R Mo; Per Omvik; Per Lund-Johansen; O L Myking
The Bergen blood pressure study: sodium intake and ambulatory blood pressure in offspring of hypertensive and normotensive families.
Blood pressure 1993;2(4):278-83.
1993: R Mo; Per Lund-Johansen; Per Omvik
The Bergen Blood Pressure Study: twenty-four-hour ambulatory blood pressure is increased in offspring of hypertensive parents.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1993;11(5):S70-1.
1993: R Mo; Per Lund-Johansen; Per Omvik
The Bergen Blood Pressure Study: ambulatory blood pressure in subjects with an accurately defined family history of hypertension or normotension.
Blood pressure 1993;2(3):197-204.
1993: R Mo; Per Omvik; Per Lund-Johansen
The Bergen Blood Pressure Study: blood pressure changes, target organ damage and mortality in subjects with high and low blood pressure over 27 years.
Blood pressure 1993;2(2):113-23.
1993: Per Omvik; O B Herland; E Thaulow; I Eide; R Midha; R R Turner
[Does antihypertensive treatment with amlodipine or enalapril affect quality of life? A multicenter study in general practice].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1993;113(11):1337-43.
1993: Per Omvik; Per Lund-Johansen
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1993;7(2):193-206.
1993: Per Omvik; Per Lund-Johansen; HK Haugland
Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1993;7(1):125-32.
1993: R Mo; P Lund-Johansen; Per Omvik
[How much is the decrease in blood pressure shown by repeated measurements during the same examination?].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1993;113(2):214-7.
1993: Per Omvik; E Thaulow; O B Herland; I Eide; R Midha; R R Turner
Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study.
Journal of hypertension 1993;11(1):103-13.
1993: Per Omvik; E Thaulow; O B Herland; I Eide; R Midha; R R Turner
A double-blind, long-term, comparative study on quality of life, safety, and efficacy during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study.
Journal of cardiovascular pharmacology 1993;22 Suppl A():S13-9.
1993: Per Lund-Johansen; Per Omvik
Cardiac effects of ACE inhibition.
Journal of cardiovascular pharmacology 1993;22 Suppl 1():S36-40.
1992: R Mo; Per Lund-Johansen; Per Omvik
The Bergen Blood Pressure Study: definition of hypertensive and normotensive families based on 27 years' follow-up.
Blood pressure 1992;1(4):230-9.
1992: Per Lund-Johansen; Per Omvik
Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
European heart journal 1992;13(2):281-6.
1992: Per Lund-Johansen; Per Omvik; W White; O Digranes; B Helland; O Jordal; T Stray
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension.
Cardiology 1992;80 Suppl 1():37-45.
1992: Per Omvik; Per Lund-Johansen; O Myking
Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise.
Journal of cardiovascular pharmacology 1992;19 Suppl 1():S90-6.
1992: Per Lund-Johansen; Per Omvik; J E Nordrehaug; W White
Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
Journal of cardiovascular pharmacology 1992;19 Suppl 1():S27-34.
1992: Per Lund-Johansen; Per Omvik; J E Nordrehaug
Long-term hemodynamic effects of antihypertensive treatment.
The Clinical investigator 1992;70 Suppl 1():S58-64.
1991: Per Omvik; Per Lund-Johansen
Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
European heart journal 1991;12(6):736-40.
1991: Per Lund-Johansen; Per Omvik
Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1991;5(3):605-15.
1991: Per Omvik; Per Lund-Johansen
Long-term haemodynamic effects of sustained-release trimazosin at rest and during exercise in essential hypertension.
European journal of clinical pharmacology 1991;40(2):131-4.
1991: Per Lund-Johansen; Per Omvik; W White; O Digranes; B Helland; O Jordal; T Stray
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension.
Postgraduate medical journal 1991;67 Suppl 5():S20-3.
1990: Per Omvik
Magnetic resonance imaging and cine computerized tomography as future tools for cardiac output measurement.
European heart journal 1990;11 Suppl I():141-3.
1990: Per Lund-Johansen; Per Omvik; W White; O Digranes; B Helland; O Jordal; T Stray
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension.
Journal of hypertension 1990;8(12):1129-36.
1990: Per Omvik; Per Lund-Johansen
The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1990;4(4):1135-43.
1990: Per Lund-Johansen; Per Omvik
Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension.
European heart journal 1990;11(6):543-51.
1990: Per Omvik; Per Lund-Johansen
Comparison of long-term hemodynamic effects at rest and during exercise of lisinopril plus sodium restriction versus hydrochlorothiazide in essential hypertension.
The American journal of cardiology 1990;65(5):331-8.
1990: Per Lund-Johansen; Per Omvik
The role of multiple action agents in hypertension.
European journal of clinical pharmacology 1990;38 Suppl 2():S89-95.
1990: Per Lund-Johansen; Per Omvik
Chronic hemodynamic effects of tiapamil and felodipine in essential hypertension at rest and during exercise.
Journal of cardiovascular pharmacology 1990;15 Suppl 4():S42-7.
1989: Per Omvik; Per Lund-Johansen
Acute haemodynamic effects of perindoprilat in essential hypertension at rest and during exercise.
Journal of hypertension 1989;7(8):633-8.
1989: Per Omvik; Per Lund-Johansen
Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1989;3(4):517-23.
1988: Per Omvik; Per Lund-Johansen; HK Haugland
Nisoldipine. Central haemodynamics at rest and during exercise in essential hypertension: acute and chronic studies.
Journal of hypertension 1988;6(2):95-103.
1987: Per Omvik; Per Lund-Johansen; HK Haugland
Central hemodynamic effects at rest and during exercise of acute and chronic treatment with nisoldipine in essential hypertension.
Journal of cardiovascular pharmacology 1987;10 Suppl 10():S182-4.
1986: Per Lund-Johansen; Per Omvik; HK Haugland
Acute and chronic hemodynamic effects of nisoldipine in essential hypertension at rest and during exercise.
Acta medica Scandinavica. Supplementum 1986;714():183-6.
1986: Per Lund-Johansen; Per Omvik; HK Haugland
Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.
British journal of clinical pharmacology 1986;21 Suppl 1():45S-54S.
1985: Per Lund-Johansen; Per Omvik; HK Haugland
The first dose hemodynamic responses to Visacor (ICI 141-292) in essential hypertension.
Acta medica Scandinavica. Supplementum 1985;693():121-5.